“Obesity is not just a comorbidity in people with heart failure with preserved ejection fraction but is a target for treatment,” said cardiac surgeon Subodh Verma, MD, PhD, FRCSC, one of the experts who will discuss new data from the STEP-HFpEF and STEP-HFpEF-DM trials.

Investigators including John B. Buse, MD, PhD, will present findings from a study of the prevalence of hypercortisolism in patients with an A1C of ≥7.5% despite receiving multiple standard-of-care therapies.

TIGHT Study Chair Irl B. Hirsch, MD, and other researchers will share new data on whether continuous glucose monitoring (CGM) can be used as effectively in the hospital as it is in the outpatient setting. The study also highlighted the challenges created by a scarcity of dedicated in-hospital diabetes care teams in community hospitals.

Investigators will discuss findings from a randomized trial that compared a regimen of basal insulin plus inhaled insulin and CGM versus usual care and CGM in adults with type 1 diabetes.

Diabetes is the leading cause of chronic kidney disease. Glucagon-like peptide-1 (GLP-1) receptor agonists hold promise as an effective new therapy to combat this condition. Richard E. Pratley, MD, and other researchers will share new data on the renal and cardiovascular benefits of GLP-1 receptor agonists.

Although SELECT was not designed as a diabetes prevention study, investigators have found clinical benefits for these patients. Using a glucagon-like peptide-1 (GLP-1) receptor agonist can reduce risk of progressing to diabetes, for example, said Steven E. Kahn, MB, ChB, one of the panelists in a symposium that will examine SELECT trial results.

Farid Mahmud, MD, will present the renal and glycemic outcomes from a trial designed to assess the impact of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in combination with insulin therapy. The session will include insights on adjunctive therapy in youth with type 1 diabetes and patient perspectives on disease management.